Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback